Second-line Treatment of Limb-Threatening Diabetic Foot Infections with Intravenous Fosfomycin

References

• Centers for Disease Control and Prevention: History of foot and ulcer among persons with diabetes- United States, 2000-2002. Morb Mortal Wkly Rep 2003; 52 (45): 1098–1102.
   PubMedGoogle Scholar
• Adler Al, Boyko EJ, Ahroni JH, Smith DG. Lower-extremity amputation in diabetes. The independent effects of peripheral vascular disease, sensory neuropathy, and foot ulcers. Diabetes Care 1999; 22 (7): 1029–1035.
   Google Scholar
• Wrobel JS, Mayfield JA, Reiber GE. Geographic varia-tion of lower-extremity major amputation in individuals with and without diabetes in the Medicare population. Diabetes Care 2001; 24 (5): 860–864.
   PubMed Web of Science ®Google Scholar
• Heller G, Ganster C, Schellschmidt H. Wie häufig sind Diabetes-bedingte Amputationen unterer Extremitäten in Deutschland? Dtsch Med Wochenschr 2004; 129 (9): 429–433.
   PubMed Web of Science ®Google Scholar
• Bagust A, Wilson E, Downs K, Perry A, Harrison D. Utility and Quality of Life in the CODE-2 study for Type-2 diabetes [poster presentation]. American Diabetic Association Conference. San Francisco, 2002.
   Google Scholar
• Hogan P, Dail T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003; 26 (3): 917–932.
   PubMed Web of Science ®Google Scholar
• Harrington C, Corea J, Zagari MJ, Klitenic J. A cost analysis of diabetic lower-extremity ulcers. Diabetes Care 2000; 23 (9): 1333–1338.
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Sandhu NS, Newton K, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 1999; 22 (2): 382–387.
   PubMed Web of Science ®Google Scholar
• Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003; 20 (6) :442-450.
   Google Scholar
• Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care 1998; 21 (5): 855–859.
   Google Scholar
• Perencevich EN, Kaye KS, Strausbaugh II, Fisman DN, Harris AD. Acceptable rates of treatment failure in osteomyelitis involving the diabetic foot: a survey of infectious diseases consultants. Clin Infect Dis 2004; 38 (4): 476–482.
   PubMed Web of Science ®Google Scholar
• Wittmann DH. Chemotherapeutic principles of difficult-to-treat infections in surgery: II. Bone and joint infections. Infection 1980; 8 (6): 330–333.
   Google Scholar
• Legat FJ, Maier A, Dittrich P, et al. Penetration of fos-fomycin into inflammatory lesions in patients with cellulitis or diabetic foot syndrome. Antimicrob Agents Chemother 2003; 47 (1): 371–374.
   PubMed Web of Science ®Google Scholar
• Mirakhur A, Gallagher MJ, Ledson MJ, Hart CA, Walshaw MJ. Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis. J Cyst Fibros 2003; 2 (1): 19–24.
   PubMedGoogle Scholar
• Zeitlinger MA, Marsik C, Georgopoulos A, Muller M, Heinz G, Joukhadar C. Target site bacterial killing of cef-pirome and fosfomycin in critically ill patients. Int J Antimicrob Agents. 2003; 21 (6): 562–567.
   PubMed Web of Science ®Google Scholar
• Monden K, Ando E, Iida M, Kumon H. Role of fos-fomycin in a synergistic combination with ofloxacin against Pseudomonas aeruginosa growing in a biofilm. J Infect Chemother 2002; 8 (3): 218–226.
   PubMedGoogle Scholar
• Meissner A, Haag R, Rahmanzadeh R. Adjuvant fos-fomycin medication in chronic osteomyelitis. Infection 1989; 17 (3): 146–151.
   PubMed Web of Science ®Google Scholar
• Goodman SN, Berlin JA The use of predicted confi-dence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med 1994; 121 (3): 200–206.
   PubMed Web of Science ®Google Scholar
• Oyibo SO, Jude EB, Tarawneh I, Nguyen HC, Harkless LB, Boulton AJ. A comparison of two diabetic foot ulcer clas-sification systems: the Wagner and the University of Texas wound classification systems. Diabetes Care 2001; 24 (1): 84–88.
   PubMed Web of Science ®Google Scholar
• Grayson ML, Gibbons GW, Balogh K, Levin E, Karchmer AW. Probing to bone in infected pedal ulcers. A clinical sign of underlying osteomyelitis in diabetic patients. JAMA 1995; 273 (9): 721–723.
   Google Scholar
• Food and Drug Administration: FDA Briefing Package October 28, 2003 AIDAC meeting: Guidance for Diabetic Foot Infections. Available at http://www.fda.gov/ohrms/dock-ets/ac/03/briefing/3997B1_01_FDA%20Diabetic%20Foot.pdf (accessed October 26, 2004).
   Google Scholar
• File TM, Tan JS. Amdinocillin plus cefoxitin versus cefoxitin alone in therapy of mixed soft tissue infections (including diabetic foot infections). Am J Med 1983; 75 (2A): 100-105.
   Google Scholar
• Hughes CE, Johnson CC, Bamberger DM, et al. Treatment and long term follow-up of foot infections in patients with diabetes or ischemia: a randomized, prospective, double-blind comparison of cefoxitin and ceftizoxime. Clin Ther 1987; 10 Suppl A: 36-49.
   Google Scholar
• Lipsky BA, Pecoraro RE, Larson SA, Hanley ME, Ahroni JH. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Arch Intern Med 1990; 150 (4): 790–797.
   PubMedGoogle Scholar
• Tan JS, Wishnow RM, Talan DA, Duncanson FP, Norden CW. Treatment of hospitalized patients with compli-cated skin and skin structure infections: double-blind, random-ized, multicenter study of piperacillin-tazobactam versus ticar-cillin-clavulanate. Antimicrob Agents Chemother 1993; 37 (8): 1580–1586.
   PubMed Web of Science ®Google Scholar
• Grayson ML, Gibbons GW, Habershaw GM, et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treat-ment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1994; 18 (5): 683–693.
   PubMed Web of Science ®Google Scholar
• Bouter KP, Visseren FLJ, van Loenhour RMM, Bartelink AKM, Erkelens DW, Diepersloot RJA. Treatment of diabetic foot infection: an open randomised comparison of imipenem/cilastatin and piperacillin/ clindamyin combination therapy. Int J Antimicrob Agents 1996; 7 (2): 143–147.
   PubMed Web of Science ®Google Scholar
• Erstad BL, McIntyre KE, Mills JL. Prospective, random-ized comparison of ampicillin/sulbactam and cefoxitin for dia-betic foot infections. Vasc Surg 1997; 31 (4): 419–426.
   Google Scholar
• Lipsky BA, Baker PD, Landon GC, Fernau R. Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens. Clin Infect Dis 1997; 24 (4): 643–648.
   PubMed Web of Science ®Google Scholar
• Graham DR, Talan DA, Nichols RL, et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin Infect Dis 2002; 35 (4): 381–389.
   PubMed Web of Science ®Google Scholar
• Siami FS, LaFleur BJ, Siami GA. Clinafloxacin versus piperacillin/tazobactam in the treatment of severe skin and soft-tissue infections in adults at a Veterans Affairs medical center. Clin Ther 2002; 24 (1): 59–72.
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 2004; 38 (1): 17–24.
   PubMed Web of Science ®Google Scholar
• Lobmann R, Ambrosch A, Seewald M, et al. Antibiotic therapy for diabetic foot infections: comparison of cephalosporines with chinolones. Diabetes Nutr Metab 2004; 17 (3): 156–162.
   PubMedGoogle Scholar
• Gerards V, Schiewe U, Gerards HH, Machka K, Höbel W, Meister W. Amoxicillin/Clavulansaure in der Therapie des bakteriell infizierten diabetischen Fuges. Fortschr Med 1999; 117 (4): 187–194.
   Google Scholar
• Valk GD, Kriegsman DMW, Assendelft WJJ. Patient education for preventing diabetic foot ulceration. The Cochrane Database of Systematic Reviews 2001, Issue 4. Art. No.: CD001488.
   Google Scholar
• Spencer S. Pressure relieving interventions for prevent-ing and treating diabetic foot ulcers. The Cochrane Database of Systematic Reviews 2000, Issue 3. Art. No.: CD002302.
   Google Scholar
• Hartemann-Heurtier A, Robert J, Jacqueminet S, et al. Diabetic foot ulcer and multidrug-resistant organisms: risk fac-tors and impact. Diabetes Med 2004; 21 (7): 710–715.
   PubMed Web of Science ®Google Scholar
• Kresken M, Hafner D, Schmitz FJ, Wichelhaus TA. Resistenzsituation bei klinisch wichtigen Infektionserregern gegentiber Antibiotika in Deutschland und im mitteleuropäis-chen Raum. Bonn: Antiinfectives Intelligence, 2003.
   Google Scholar
• Slater RA, Lazarovitch T, Boldur I, et al. Swab cultures accurately identify bacterial pathogens in diabetic foot wounds not involving bone. Diabet Med 2004; 21 (7): 705–709.
   PubMed Web of Science ®Google Scholar
• Nilsson Al, Berg OG, Aspevall O, Kahlmeter G, Andersson DI. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother 2003; 47 (9): 2850–2858.
   PubMed Web of Science ®Google Scholar
• Arca P, Reguera G, Hardisson C. Plasmid-encoded fos-fomycin resistance in bacteria isolated from the urinary tract in a multicentre survey. J Antimicrob Chemother 1997; 40 (3): 393–399.
   PubMed Web of Science ®Google Scholar
• Andreu A, Abs JI, Gobernado M, et al. Etiologia y sensibilidad a los antimicrobianos de los uropat6genos cau-santes de la infecci6n urinaria baja adquirida en la comunidad. Estudio nacional multicentrico. Enferm Infecc Microbiol Clin 2005; 23 (1): 4–9.
   PubMed Web of Science ®Google Scholar
• Quentin C, Arpin C, Dubois V, et al. Antibiotic resis-tance rates and phenotypes among isolates of Enterobacteriaceae in French extra-hospital practice. Eur J Clin Microbiol Infect Dis 2004; 23 (3): 185–93.
   PubMed Web of Science ®Google Scholar
• Marchese A, Gualco L, Debbia EA, Schito GC, Schito AM. In vitro activity of fosfomycin against gram-negative uri-nary pathogens and the biological cost of fosfomycin resis-tance. Int J Antimicrob Agents 2003; 22 Suppl 2: 53–59.
   PubMed Web of Science ®Google Scholar
• Kahlmeter G. Prevalence and antimicrobial susceptibili-ty of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study. Int J Antimicrob Agents 2003; 22 Suppl 2: 49–52.
   PubMed Web of Science ®Google Scholar
• Olsson-Liljequist B, Burman LG. Introducing fosfomycin for surgical prophylaxis- emergence of resistance in aerobic faecal gram-negative bacteria of in-patients, but not among strains causing infection after elective colorectal procedures. Scand J Infect Dis 1993; 25 (6): 725–733.
   PubMed Web of Science ®Google Scholar
• van Baal JG. Surgical treatment of the infected diabetic foot. Clin Infect Dis 2004; 39 Suppl 2: S123–128.
   PubMed Web of Science ®Google Scholar